CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models [RNA-seq]
RNA-seq (gene expression) · mouse · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 12 samples: 3 × Myc-Cap, DMSO treated vs 3 × Myc-Cap, YJ1206 treated 24 h vs 3 × Myccap Tumor Vehicle vs 3 × Myccap Tumor YJ1206Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical modelsThe Journal of clinical investigation · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE283088_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1191845 and SRA study SRP548221. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8655794 Myc-Cap, DMSO treated - 1 Myc-Cap, DMSO treated
- GSM8655795 Myc-Cap, DMSO treated - 2 Myc-Cap, DMSO treated
- GSM8655796 Myc-Cap, DMSO treated - 3 Myc-Cap, DMSO treated
- GSM8655797 Myc-Cap, YJ1206 treated 24 hr - 1 Myc-Cap, YJ1206 treated…
- GSM8655798 Myc-Cap, YJ1206 treated 24 hr - 2 Myc-Cap, YJ1206 treated…
- GSM8655799 Myc-Cap, YJ1206 treated 24 hr - 3 Myc-Cap, YJ1206 treated…
- GSM9005554 Myccap Tumor Vehicle - 1 Myccap Tumor Vehicle
- GSM9005555 Myccap Tumor Vehicle - 2 Myccap Tumor Vehicle
- GSM9005556 Myccap Tumor Vehicle - 3 Myccap Tumor Vehicle
- GSM9005557 Myccap Tumor YJ1206 - 1 Myccap Tumor YJ1206
- GSM9005558 Myccap Tumor YJ1206 - 2 Myccap Tumor YJ1206
- GSM9005559 Myccap Tumor YJ1206 - 3 Myccap Tumor YJ1206
- GSE307388 Immune checkpoint blockade augments lymphodepleting chemotherapy-induced antitumor immunity by expanding effector CD8+ T cell clones in preclinical models of cancer 12 samples shares preclinical, antitumor, immunity
- GSE255807 Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12 (RNA-Seq) 16 samples shares cdk12, rna-seq
- GSE254388 CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality [RNA-Seq] 14 samples shares cdk12, rna-seq
- GSE310108 SETDB1/HUSH modulates Xist RNA levels during establishment of X chromosome inactivation [RNA-Seq] 112 samples shares inactivation, rna-seq
- GSE286461 MAX inactivation deregulates the MYC network and induces neuroendocrine neoplasia in multiple tissues [RNA-seq] 46 samples shares inactivation, rna-seq
- GSE293456 A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDAC 30 samples shares preclinical, triggers
- GSE269251 Ehmt2 Inactivation in Pancreatic Epithelial Cells Shapes the Transcriptional Landscape and Inflammation Response of the Whole Pancreas [RNA-seq] 22 samples shares inactivation, rna-seq
- GSE319318 Inactivation of CDKN2A-ARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment [RNA-Seq] 20 samples shares inactivation, rna-seq
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.